Screener
Polaryx Therapeutics, Inc. PLYX Shares Issued Price Per Share
Shares Issued Price Per Share at other companies
Other financials
Where this comes from
Reported directly by Polaryx Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SharesIssuedPricePerShare.
The source filing: Polaryx Therapeutics, Inc.’s 10-K, filed March 24, 2026.
- Filed
- Mar 24, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001213900-26-033064
In January 2025, the Company entered into a Share Placement Agreement with Rush and Mstone, pursuant to which the Company issued 277,823 shares to Rush and 3,426,484 shares to Mstone at a price per share of $1.17 in exchange for an exclusive gene therapy patent license (See Note 4 and Note 9).
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Polaryx Therapeutics, Inc.'s shares issued price per share?
- Polaryx Therapeutics, Inc. (PLYX) reported shares issued price per share of $1.17 in Q1 2025.
- What does shares issued price per share mean?
- This metric represents the weighted average or specific issuance price at which common equity shares were sold to investors during a financing event. It provides insight into the valuation at which the company raised capital and the dilution impact on existing shareholders. Tracking this helps investors understand the company's historical cost of equity and the market's perception of value at the time of capital raises.
Ask your AI about Polaryx Therapeutics, Inc.'s shares issued price per share.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude